Nifty
Sensex
:
:
11504.95
38845.82
-11.15 (-0.10%)
-134.03 (-0.34%)

Pharmaceuticals & Drugs - Global

Rating :
70/99

BSE: 524816 | NSE: NATCOPHARM

890.80
18-Sep-2020
  • Open
  • High
  • Low
  • Previous Close
  •  791.20
  •  927.90
  •  791.20
  •  773.25
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  7395084
  •  66210.73
  •  927.90
  •  402.55

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 16,176.74
  • 36.73
  • 2
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 16,283.54
  • 0.70%
  • 4.15

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 48.93%
  • 1.51%
  • 14.98%
  • FII
  • DII
  • Others
  • 20.4%
  • 11.93%
  • 2.25%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 16.45
  • 20.47
  • 1.21

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 24.14
  • 30.08
  • 3.07

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 29.46
  • 36.78
  • 9.86

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 28.25
  • 26.16
  • 20.74

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 5.26
  • 5.63
  • 4.16

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 20.55
  • 21.82
  • 14.93

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Jun 20
Jun 19
Var%
Mar 20
Mar 19
Var%
Dec 19
Dec 18
Var%
Sep 19
Sep 18
Var%
Net Sales
563.40
492.30
14.44%
454.80
455.70
-0.20%
482.20
556.70
-13.38%
485.70
543.50
-10.63%
Expenses
392.30
301.00
30.33%
326.50
307.40
6.21%
353.50
348.30
1.49%
351.40
323.00
8.79%
EBITDA
171.10
191.30
-10.56%
128.30
148.30
-13.49%
128.70
208.40
-38.24%
134.30
220.50
-39.09%
EBIDTM
30.37%
38.86%
14.01%
32.54%
26.69%
37.43%
27.65%
40.57%
Other Income
18.70
21.00
-10.95%
22.40
31.00
-27.74%
30.80
23.30
32.19%
33.20
40.00
-17.00%
Interest
3.70
6.50
-43.08%
3.50
5.20
-32.69%
5.30
6.30
-15.87%
6.20
5.00
24.00%
Depreciation
28.00
22.00
27.27%
30.50
21.70
40.55%
25.40
20.70
22.71%
21.90
20.20
8.42%
PBT
158.10
183.80
-13.98%
116.70
152.40
-23.43%
128.80
204.70
-37.08%
139.40
235.30
-40.76%
Tax
36.00
41.00
-12.20%
23.50
32.00
-26.56%
24.40
45.40
-46.26%
21.70
53.70
-59.59%
PAT
122.10
142.80
-14.50%
93.20
120.40
-22.59%
104.40
159.30
-34.46%
117.70
181.60
-35.19%
PATM
21.67%
29.01%
7.11%
26.42%
21.65%
28.62%
24.23%
33.41%
EPS
6.71
7.84
-14.41%
5.12
6.61
-22.54%
5.73
8.75
-34.51%
6.46
9.97
-35.21%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Net Sales
1,986.10
2,094.50
2,184.80
2,020.20
1,141.30
825.28
738.89
660.53
523.72
459.68
456.70
Net Sales Growth
-3.03%
-4.13%
8.15%
77.01%
38.29%
11.69%
11.86%
26.12%
13.93%
0.65%
 
Cost Of Goods Sold
5,033.70
354.20
411.10
599.10
341.10
242.37
233.23
242.80
203.08
186.08
210.06
Gross Profit
-3,047.60
1,740.30
1,773.70
1,421.10
800.20
582.90
505.67
417.73
320.64
273.60
246.64
GP Margin
-153.45%
83.09%
81.18%
70.34%
70.11%
70.63%
68.44%
63.24%
61.22%
59.52%
54.00%
Total Expenditure
1,423.70
1,299.70
1,256.40
1,336.80
868.70
611.90
559.56
510.60
414.38
369.11
365.29
Power & Fuel Cost
-
59.60
56.20
50.50
43.70
43.24
44.77
38.75
26.88
21.41
15.13
% Of Sales
-
2.85%
2.57%
2.50%
3.83%
5.24%
6.06%
5.87%
5.13%
4.66%
3.31%
Employee Cost
-
355.90
325.60
243.20
189.60
136.92
112.77
102.29
80.05
66.39
57.25
% Of Sales
-
16.99%
14.90%
12.04%
16.61%
16.59%
15.26%
15.49%
15.28%
14.44%
12.54%
Manufacturing Exp.
-
207.70
182.60
141.20
105.20
73.04
76.57
65.10
43.32
40.18
38.80
% Of Sales
-
9.92%
8.36%
6.99%
9.22%
8.85%
10.36%
9.86%
8.27%
8.74%
8.50%
General & Admin Exp.
-
130.50
105.50
88.10
73.40
63.66
56.21
39.49
32.37
27.32
19.61
% Of Sales
-
6.23%
4.83%
4.36%
6.43%
7.71%
7.61%
5.98%
6.18%
5.94%
4.29%
Selling & Distn. Exp.
-
137.20
136.90
143.20
91.60
37.36
26.16
14.82
19.02
13.24
12.56
% Of Sales
-
6.55%
6.27%
7.09%
8.03%
4.53%
3.54%
2.24%
3.63%
2.88%
2.75%
Miscellaneous Exp.
-
54.60
38.50
71.50
24.10
15.31
9.85
7.36
9.66
14.50
12.56
% Of Sales
-
2.61%
1.76%
3.54%
2.11%
1.86%
1.33%
1.11%
1.84%
3.15%
2.60%
EBITDA
562.40
794.80
928.40
683.40
272.60
213.38
179.33
149.93
109.34
90.57
91.41
EBITDA Margin
28.32%
37.95%
42.49%
33.83%
23.89%
25.86%
24.27%
22.70%
20.88%
19.70%
20.02%
Other Income
105.10
130.20
40.40
13.90
9.90
14.91
16.71
12.41
9.14
4.64
4.62
Interest
18.70
19.30
15.40
18.50
22.90
31.68
36.62
26.31
23.04
14.20
14.69
Depreciation
105.80
81.00
66.20
54.40
51.00
47.27
30.44
22.12
15.91
15.88
19.73
PBT
543.00
824.70
887.20
624.40
208.60
149.34
128.98
113.90
79.54
65.12
61.61
Tax
105.60
182.30
192.00
139.50
52.80
3.95
30.87
36.44
21.07
13.21
13.66
Tax Rate
19.45%
22.11%
21.64%
22.34%
25.31%
2.94%
23.93%
35.61%
26.49%
20.29%
22.17%
PAT
437.40
644.40
696.20
486.00
157.10
134.62
102.74
71.87
59.61
53.51
48.72
PAT before Minority Interest
439.50
642.40
695.20
484.90
155.80
130.27
98.11
65.88
58.47
51.91
47.95
Minority Interest
2.10
2.00
1.00
1.10
1.30
4.35
4.63
5.99
1.14
1.60
0.77
PAT Margin
22.02%
30.77%
31.87%
24.06%
13.77%
16.31%
13.90%
10.88%
11.38%
11.64%
10.67%
PAT Growth
-27.59%
-7.44%
43.25%
209.36%
16.70%
31.03%
42.95%
20.57%
11.40%
9.83%
 
EPS
24.02
35.39
38.23
26.69
8.63
7.39
5.64
3.95
3.27
2.94
2.68

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Shareholder's Funds
3,489.00
3,072.20
1,649.30
1,295.70
846.05
725.88
533.54
473.63
352.43
305.74
Share Capital
36.50
36.90
34.90
34.80
33.23
33.07
31.37
31.15
28.15
28.15
Total Reserves
3,421.70
3,011.40
1,599.00
1,251.20
812.82
692.80
502.17
442.49
324.29
277.59
Non-Current Liabilities
83.40
47.10
37.70
28.00
119.23
150.67
191.46
171.34
160.44
146.34
Secured Loans
0.00
0.00
0.00
0.00
94.03
92.20
135.62
133.88
125.21
114.02
Unsecured Loans
0.00
0.00
0.00
0.00
2.99
3.28
2.21
0.22
0.22
5.49
Long Term Provisions
71.00
32.40
21.90
12.50
9.50
11.09
8.62
6.59
8.67
0.00
Current Liabilities
728.70
592.00
626.50
493.10
413.74
312.28
344.87
259.35
193.38
97.29
Trade Payables
217.00
269.10
262.70
275.60
125.30
109.79
105.85
92.36
76.60
82.72
Other Current Liabilities
109.80
133.40
127.10
114.20
118.56
102.18
90.21
81.91
43.86
8.79
Short Term Borrowings
386.30
173.20
221.60
98.40
168.54
98.63
147.74
81.64
72.02
0.00
Short Term Provisions
15.60
16.30
15.10
4.90
1.33
1.69
1.07
3.44
0.91
5.78
Total Liabilities
4,303.10
3,715.10
2,317.60
1,821.70
1,384.05
1,195.71
1,080.41
905.20
707.31
554.31
Net Block
1,227.20
1,018.60
833.00
710.10
709.97
644.74
582.75
319.56
270.16
261.80
Gross Block
1,696.10
1,407.60
1,158.70
983.30
939.98
819.89
726.97
440.33
374.37
356.86
Accumulated Depreciation
468.90
389.00
325.70
273.20
225.82
171.11
140.57
117.34
104.21
95.06
Non Current Assets
1,955.90
1,584.40
1,230.30
984.70
901.08
827.57
749.94
612.42
460.37
361.69
Capital Work in Progress
637.60
480.00
336.30
211.80
128.96
123.78
105.84
164.43
75.98
39.60
Non Current Investment
19.90
8.10
0.10
0.10
1.57
1.57
1.54
61.79
61.79
60.29
Long Term Loans & Adv.
68.90
75.40
60.40
62.10
57.03
54.25
57.20
66.22
51.49
0.00
Other Non Current Assets
2.30
2.30
0.50
0.60
3.54
3.24
2.61
0.42
0.96
0.00
Current Assets
2,347.20
2,130.70
1,087.30
837.00
482.97
368.14
330.48
292.79
246.95
192.62
Current Investments
148.70
68.40
32.10
22.10
0.12
0.32
0.81
0.74
0.82
0.31
Inventories
529.00
438.40
348.90
357.30
220.00
181.12
146.02
110.39
102.23
77.44
Sundry Debtors
506.20
637.50
475.20
261.60
192.43
118.80
129.71
94.69
70.98
57.24
Cash & Bank
279.50
183.70
35.80
45.20
13.36
11.05
10.78
36.63
32.37
8.12
Other Current Assets
883.80
53.20
25.80
25.40
57.06
56.85
43.14
50.34
40.55
49.52
Short Term Loans & Adv.
784.20
749.50
169.50
125.40
40.97
52.46
38.85
41.84
36.73
49.05
Net Current Assets
1,618.50
1,538.70
460.80
343.90
69.23
55.85
-14.39
33.44
53.56
95.32
Total Assets
4,303.10
3,715.10
2,317.60
1,821.70
1,384.05
1,195.71
1,080.42
905.21
707.32
554.31

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Cash From Operating Activity
668.80
463.60
345.80
112.20
92.67
144.03
61.19
64.94
36.99
77.37
PBT
824.70
887.20
624.40
208.60
134.22
128.98
102.32
79.54
65.12
61.61
Adjustment
14.10
75.60
100.20
90.50
68.14
65.72
48.87
36.97
38.87
44.21
Changes in Working Capital
8.80
-294.60
-253.00
-140.70
-85.96
-16.11
-67.39
-27.97
-48.50
-11.24
Cash after chg. in Working capital
847.60
668.20
471.60
158.40
116.41
178.58
83.80
88.54
55.49
94.58
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-178.80
-204.60
-125.80
-46.20
-23.74
-34.55
-22.61
-23.60
-18.50
-17.21
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-612.20
-1,115.50
-299.40
-175.50
-114.75
-108.92
-107.07
-126.94
-88.78
-60.85
Net Fixed Assets
-436.10
-392.40
-299.40
-303.91
-100.13
-99.70
-102.47
-151.51
-71.49
-38.56
Net Investments
-94.80
-54.80
-1.00
37.47
-42.37
-11.33
-2.67
-3.71
8.04
-20.13
Others
-81.30
-668.30
1.00
90.94
27.75
2.11
-1.93
28.28
-25.33
-2.16
Cash from Financing Activity
-50.90
650.90
-47.70
154.00
29.07
-35.27
26.31
62.78
77.10
-34.14
Net Cash Inflow / Outflow
5.70
-1.00
-1.30
90.70
6.99
-0.15
-19.57
0.78
25.31
-17.63
Opening Cash & Equivalents
21.70
23.50
24.20
-164.10
10.22
9.95
34.64
31.70
6.53
27.39
Closing Cash & Equivalent
28.30
21.70
23.50
-74.20
12.44
10.22
9.95
34.64
31.70
6.95

Financial Ratios

Consolidated /

Standalone
Description
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Book Value (Rs.)
189.49
165.22
93.63
73.91
50.91
219.48
170.06
152.06
125.21
108.62
ROA
16.02%
23.05%
23.43%
9.72%
10.10%
8.62%
6.64%
7.25%
8.23%
8.88%
ROE
19.75%
29.70%
33.21%
14.62%
16.57%
15.58%
13.08%
14.16%
15.77%
17.02%
ROCE
23.71%
35.28%
39.21%
18.04%
15.62%
18.02%
16.04%
15.72%
15.90%
18.83%
Fixed Asset Turnover
1.35
1.72
1.93
1.23
0.95
0.96
1.14
1.30
1.27
1.38
Receivable days
99.65
92.22
65.12
70.27
67.76
60.90
61.30
56.98
50.31
47.13
Inventory Days
84.29
65.25
62.41
89.35
87.33
80.17
70.04
73.13
70.50
62.46
Payable days
72.53
81.42
78.30
85.42
73.36
74.09
73.36
79.03
83.93
87.92
Cash Conversion Cycle
111.42
76.05
49.23
74.21
81.73
66.99
57.98
51.07
36.89
21.67
Total Debt/Equity
0.11
0.06
0.14
0.09
0.37
0.33
0.63
0.55
0.62
0.39
Interest Cover
43.73
58.61
34.75
10.11
5.24
4.52
4.89
4.45
5.59
5.19

News Update:


  • Natco Pharma - Quarterly Results
    12th Aug 2020, 14:26 PM

    Read More
  • Natco Pharma’s arm enters into settlement agreement with Celgene
    10th Jul 2020, 11:22 AM

    The company’s arm entered into settlement agreement for the product Lenalidomide Capsules in Canada

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.